Page 41 - Medication Guide News Today

10.05.2022 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that data for six approved medicines and pipeline candidates in more than 25 types of cancer will be presented at the 2022 American Society of Clinical Oncology ...

Axsome is committed to providing patients uninterrupted access to Sunosi and advancing research for patients living with sleep disorders Insurance coverage for...

In the US, QUVIVIQ (daridorexant) CIV 25 mg and 50 mg tablets are indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance1QUVIVIQ

02.05.2022 - In the US, QUVIVIQ (daridorexant) CIV 25 mg and 50 mg tablets are indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance1QUVIVIQ becomes Idorsia’s first commercial product ... Seite 1

Investegate announcements from Idorsia Pharmaceuticals Ltd, Idorsia’s new treatment QUVIVIQ (daridorexant) is now available in the US for adults living with insomnia

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - April 26, 2022 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2022. Business highlights PIVLAZ

Press release content from Business Wire. The AP news staff was not involved in its creation.

– If approved, Actemra would be the first U.S. FDA-approved immunomodulator for the treatment of COVID-19 in hospitalized patients – – Since the begin

Data from NOVA study further support the efficacy and safety of natalizumab IV when administered every six weeks as compared to the approved every...